Osprey Private Wealth LLC Raises Position in Zoetis Inc. (NYSE:ZTS)

Osprey Private Wealth LLC increased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 22.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,120 shares of the company's stock after purchasing an additional 3,175 shares during the quarter. Zoetis accounts for 1.7% of Osprey Private Wealth LLC's investment portfolio, making the stock its 28th biggest position. Osprey Private Wealth LLC's holdings in Zoetis were worth $2,819,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Mission Wealth Management LP raised its position in Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after purchasing an additional 59 shares during the period. VeraBank N.A. raised its position in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares during the period. HUB Investment Partners LLC raised its position in Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after purchasing an additional 62 shares during the period. Coppell Advisory Solutions LLC raised its position in Zoetis by 18.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after purchasing an additional 64 shares during the period. Finally, Deseret Mutual Benefit Administrators increased its position in shares of Zoetis by 6.6% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after acquiring an additional 65 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 2.7%

Shares of ZTS traded down $4.55 during trading hours on Friday, reaching $164.27. 2,973,481 shares of the company traded hands, compared to its average volume of 2,551,303. The company's fifty day moving average price is $158.26 and its two-hundred day moving average price is $164.09. The company has a market capitalization of $73.13 billion, a price-to-earnings ratio of 30.03, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the previous year, the firm posted $1.38 earnings per share. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is currently 35.91%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of analyst reports. Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Finally, UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $212.75.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now owns 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.18% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.